
After years of writing about my own cancer, I sat down to write my 94-year-old mother's obituary and learned how differently the two forms hit.

After years of writing about my own cancer, I sat down to write my 94-year-old mother's obituary and learned how differently the two forms hit.

Nicole Echols discusses Lung Cancer Initiative, reducing lung cancer stigma, biomarker testing, early detection and support for patients and caregivers.

Dr. Jia Luo explains how chemotherapy, targeted therapy and immunotherapy work for lung cancer, plus tips for managing treatment side effects.

Jill May, RN, BSN, OCN, of Allina Health Cancer Institute, guided a liver cancer patient and his caregiver wife through three years of treatment, setbacks and ultimately hospice care with unwavering devotion.

Long-term survivorship in small cell lung cancer was not expected 20 years ago. A radiation oncologist explains what that shift means for patients today.

Janet Fuller, DNP, RN, OCN, of Vanderbilt University Medical Center, helped two young breast cancer patients form a support group that now guides dozens of women through diagnosis and treatment.

A decade after my double mastectomy, I went to the cardiologist worried about my heart and left having shared my breast cancer story with a stranger.

Three years after ringing the bell for lymphoma, the cancer came back in my brain. Choosing hospice care was the hardest decision I have ever had to make.

Long-term follow-up of a trial found patients with recurrent prostate cancer lived longer after receiving the pTVG-HP vaccine than GM-CSF alone.

ASCO updated its guideline to recommend broader first-line HER2-targeted treatment options, with immunotherapy for eligible patients with PD-L1 expression of 1% or higher.

Cancer drugs sit in a protected class under Medicare Part D, but plans can still deny coverage. A researcher from Vanderbilt found that many of those denials do not hold up under outside review.

Andrew Evens, DO & Joanna Rhodes, MD on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across New Jersey.

In five months, we lost the land, the travel and the retirement we had planned together, and then learned my husband's lymphoma had come back in his brain.

Cat-camel exercises can gently improve spine mobility and comfort. Learn how this simple movement can support flexibility during cancer recovery.

In the phase 2 SANRECO trial, 88% of patients with polycythemia vera kept hematocrit below 45% without a phlebotomy. Lead investigator Dr. Marina Kremyanskaya explains what that could mean day to day.

Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found.

Juanita Segura shares her nearly 12-year lung cancer journey, the power of community and why she advocates for biomarker testing and hope.

Learn what lung cancer stages mean, why biomarker testing matters, and how advances in precision medicine are changing treatment for patients.

In the phase 2 KEYPAD trial, Keytruda plus Xgeva shrank tumors in 31% of patients with advanced clear cell kidney cancer after prior treatment.

Leslie Waltke demonstrates gentle trunk rotations to help improve mobility in the lower and upper spine. Learn how to safely perform this exercise at home.

The phase 3 DESTINY-Lung04 trial met its main goal of keeping cancer from growing longer than chemotherapy plus immunotherapy did.

After reading another cancer survivor’s story, Sue McCarthy reflects on her own experience with guilt, her stage 3B lung cancer diagnosis and how helping others through a cancer support group helped her find confidence and purpose.

Cara Curcio’s melanoma journey changed her life as a wife and mother, but treatment, family and hope have kept her moving forward.

Nicole Schultz was treated for acute myeloid leukemia as a teenager. Two decades later, chronic graft-versus-host disease and ongoing survivorship monitoring remain part of her care.

A gynecologic oncologist on the testing that shapes treatment, the side effect not to push through and why fertility questions can't wait.

Sixteen years after treatment, cancer fatigue is still my constant shadow. I can't cure it, so I've learned to manage it instead of letting it manage me.

Dr. Priscilla Merriam discusses why sarcoma is often mistaken for a benign growth, how treatment differs across more than 150 types and where patients can find expert care.

The FDA granted accelerated approval to Zenbexus with daratumumab and hyaluronidase-fihj and dexamethasone for previously treated multiple myeloma.

Sixteen years after my own cancer journey, I find myself reflecting on the lasting shadows of cancer and the connection survivors can offer one another.

Genomic testing can show whether a targeted treatment may be an option. In a Medicare study, fewer than 1 in 5 patients with cancer received it in 2023.